A central lab relationship for a five-year development programme looks very different from a one-off engagement for a single study. Contracts need to account for potential assay changes, protocol amendments, and personnel transitions over the programme’s life. Getting the governance structure right at the outset generally determines how smoothly a sponsor and lab partner adapt when, not if, something changes mid-programme.
Structuring the Master Services Agreement for the Long Term
Most multi-year central lab relationships are built on a Master Services Agreement (MSA) paired with individual Work Orders or Task Orders for each study within the programme. The MSA generally establishes the overarching commercial and contractual terms, while each Work Order or Task Order defines the study-specific scope, testing requirements, and pricing. This structure lets a sponsor add a new study to an existing programme without renegotiating baseline terms each time.
For a programme expected to run five years or more, sponsors are generally advised to build a defined change-order process directly into the MSA, specifying how scope changes, new assay additions, or pricing adjustments will be documented and approved. Without this built in from the start, even a routine mid-programme adjustment can turn into a lengthy renegotiation, since the parties would otherwise fall back on informal side agreements that are harder to audit later. Sponsors evaluating central laboratory services for this kind of long-term arrangement are generally advised to review a prospective partner’s standard MSA template for these governance mechanisms before the first study under the programme begins.
Managing Assay Changes Without Disrupting Data Continuity
Over a multi-year programme, it is common for an assay manufacturer to update a reagent lot, for a method to be replaced by a newer platform, or for a reference range to be revised based on updated population data. Each carries a risk: if not properly documented and bridged, a shift in assay methodology partway through a programme can make results from before and after the change difficult to compare directly, complicating both interim analyses and the eventual integrated safety and efficacy summary.
A well-structured lab partnership generally addresses this through a documented assay change control process, typically including advance notification to the sponsor, a defined justification for the change, and where applicable, a bridging or comparability study demonstrating how results under the new method relate to results under the old one. Sponsors are advised to confirm how a prospective lab partner handles this before signing a multi-year agreement, since the volume of assay updates a programme is likely to encounter tends to scale with both its duration and its testing menu complexity.
Where an Established Lab and Quality Infrastructure Matters
Long-programme continuity depends heavily on whether a lab partner’s broader organizational infrastructure can support consistent operations across several years and, often, several geographies. Tigermed lists Central Laboratories among its integrated capabilities and operates within a global network the company reports at more than 180 offices and locations across Asia Pacific, Europe, North America, Latin America, and Africa. In North America specifically, the company reports more than 200 employees in the US and Canada, with clinical operations teams across 27 US states and a network of more than 700 clinical trial sites across 45+ states.
This kind of infrastructure typically operates alongside a company’s quality assurance function, directly relevant to sustaining consistent lab operations over time. Tigermed‘s QA team, described by the company as operating independently from its clinical operations groups, reports more than 40 in-house auditors supporting GCP, GLP, and GMP audit work — the kind of ongoing internal oversight that helps confirm a lab partner’s processes stay consistent as a programme moves through multiple years and potential staffing changes.
How Protocol Amendments Ripple Into Lab Operations
Protocol amendments are a near-certainty over a multi-year programme, and each one can carry direct consequences for lab operations. Tufts CSDD research has documented that substantial protocol amendments are common across clinical development, with their prevalence and frequency varying by development phase.
A protocol amendment that affects biomarkers, specimen collection requirements, visit schedules, or eligibility may require the central lab to update collection materials, laboratory documentation, or site training, depending on the operational impact of the change. This preparation should be planned alongside the amendment process so that required lab changes are ready for implementation once the amended protocol becomes effective at the relevant sites, Sponsors are generally advised to confirm in advance how amendment-driven changes are prioritized and turned around, since a lab treating each amendment as an ad hoc request is more likely to introduce delay into an already lengthy amendment cycle.
Maintaining Continuity Across a Five-Year Programme
Beyond individual assay and protocol changes, a five-year programme should also account for potential changes in the personnel managing it on both the sponsor and lab sides. Regular governance meetings — often structured as a joint operating committee reviewing performance metrics, open issues, and upcoming changes — are generally used to preserve institutional knowledge as staff transition on and off the programme.
Documentation discipline becomes especially important here: a well-maintained record of assay validations, protocol amendment impacts, and prior governance decisions allows a new team member on either side to get up to speed without relying entirely on the memory of people no longer involved. Programmes lacking this kind of documented history tend to see continuity problems resurface with each round of staff turnover, regardless of how capable any individual team member is.
Bringing the Structure Together
An MSA with a built-in change process, a documented assay change control procedure, a clear plan for absorbing protocol amendments, and a governance cadence for staff continuity are not independent requirements — each supports the others across a programme’s duration. Sponsors evaluating a partner for central clinical laboratories work spanning several years are generally advised to request examples of how a prospective partner has managed each element on a comparable long-duration programme, rather than assuming general lab capability translates automatically into multi-year continuity.
Companies such as Tigermed, which report a multi-region office network alongside an independently structured quality assurance function, illustrate one way these elements can be organized for programmes of this length. As with any long-term vendor relationship, sponsors are advised to confirm current governance practices and request references specific to programmes of comparable duration before finalizing a selection.
